Touchstone
Last syncNov 1, 2026, 6:55 PM ET

LBRX

Lb Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$39.70Close $1.0BMarket cap $14.61 – $49.4852-week range Nov 5, 2026Next report

Highlights

Strengths

  • Leading the market RS 93 · stronger than 93% of stocks over 12 months

Cautions

  • Trend not confirmed 7 of 8 conditions · under the 50-day
  • Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 11, 2026
Off 12-month high 20%
1wk up 2.5% price change
1mo up 3.4% price change
12-month return up 144% market up 11% · its own up 143%
F-score — — Not assessed
Altman Z — Unknown
P/E — price / earnings
PEG — P/E / EPS growth
P/B 3.3× price / book
Earnings yield down 3.3% EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth — year on year
EPS growth — latest quarter
Sales growth — latest quarter
ROE down 8% return on equity
Free cash margin — -$35.3M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest

Trade setup

ATR% 5.7% $2.26 a day · 2×ATR $35.19
RS 93 / 99 vs the universe
Trend 7 / 8 under the 50-day
Relative volume 1.2× vs 50-day average
Up/down volume 0.96 50 sessions
Implied move — no option chain · report Nov 5, 2026
Trend template · 7 of 8
  • Price above the 50-day average: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Shareholders diluted The share count rose 9953.2% over the year, from 0m to 25m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported Aug 11, 2026
Results reaction Aug 11, 2026-1% vs market2 sessions after results

Financials

2 fiscal years · from filings
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$25.2M
-$100M $0 FY24 FY25 FY2024 · -$63.1M FY2025 · -$25.2M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$35.3M
-$100M $0 FY24 FY25 FY2024 · -$53.8M FY2025 · -$35.3M
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $500M FY24 FY25 FY2024 · Cash $23.0M FY2025 · Cash $250.2M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 25.30m +9953.2% since FY2024
25.30m 251.66k FY24 FY25 FY2024 · 251.66k FY2025 · 25.30m
  FY2024Dec 31, 2024 FY2025Dec 31, 2025
Net income -$63.1M -$25.2M
Earnings per share -$176.15 -$3.13
Free cash flow -$53.8M -$35.3M
Cash $23.0M $250.2M
Shareholders' equity -$94.6M $301.3M
Shares outstanding 251.66k 25.30m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 11, 2026 Quarterly ↗ Jun 30, 2026 42d
May 12, 2026 Quarterly ↗ Mar 31, 2026 42d
Mar 26, 2026 Annual ↗ Dec 31, 2025 85d
Nov 6, 2025 Quarterly ↗ Sep 30, 2025 37d

Current reports

FiledDisclosed
Sep 15, 2026 Director or officer change · Regulation FD ↗
Sep 3, 2026 Director or officer change · Regulation FD ↗
Aug 11, 2026 Results ↗
Jul 29, 2026 Material agreement · Unregistered share sale · Regulation FD ↗
Jul 22, 2026 Other events ↗
Jun 10, 2026 Director or officer change ↗
Jun 9, 2026 Shareholder vote ↗
May 12, 2026 Results ↗
Mar 26, 2026 Results ↗
Mar 16, 2026 Director or officer change ↗
Mar 10, 2026 Director or officer change · Regulation FD ↗
Feb 5, 2026 Material agreement · Unregistered share sale · Regulation FD · Other events ↗